In a quest to grow its mRNA-processing empire, pharmaceutical company Moderna has turned a spotlight on the life sciences powerhouse of United Kingdom. And it is that, according to informa Fierce Pharmathe company has identified in the Harwell Science Campus in Oxfordshire (England) as the home of his next Innovation and Technology Center.
It is expected to come into operation for 2025. The facility, also known as MITCwill aim to supply the UK with mRNA vaccines for a “broad range” of respiratory diseases, according to the company. Specifically, the facility will work on vaccines for diseases such as COVID-19, seasonal flu y respiratory syncytial virus (VRS), along with other possible vaccines, have added.
The location places Moderna within the ‘Golden Triangle’ of the United Kingdom, rich in biopharmaceuticals, and comprising the vertices of London, Oxford and Cambridge
The location places Moderna within the ‘Golden Triangle’ of the United Kingdom, rich in biopharmaceuticals, and comprising the vertices of London, Oxford y Cambridge.
Construction will begin at some as-yet-undetermined time in 2023. Moderna believes that this entrepreneurial effort will create “hundreds of jobs” both during construction and in subsequent years.
It should be recalled that Moderna reached a preliminary agreement with the UK last summer to establish the MITC as part of an effort to strengthen access to “rapid response capabilities to a pandemic”. At the time, Moderna commented that he was designing the installation to activate “urgently”. The measure falls within the “100 Day Mission” of the United Kingdom, which aims to mitigate the force of future pandemics.
